Recro Pharma, Inc. (REPH) financial statements (2022 and earlier)

Company profile

Business Address 1 E. UWCHLAN AVE, SUITE 112
EXTON, PA 19341
State of Incorp. PA
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments25,21723,76019,14838,51464,48264,48319,779
Cash and cash equivalents25,21723,76019,14838,51460,98464,48319,779
Short-term investments    3,498  
Receivables11,9139,03314,38912,8669,68610,4118,616
Inventory, net of allowances, customer advances and progress billings8,91711,61215,07210,6999,8398,7468,982
Inventory8,91711,61215,07210,6999,8398,7468,982
Prepaid expense      757
Contract with customer, asset8,5657,3308,8515,201
Deferred costs      542
Other undisclosed current assets2,9172,3342,7003,8613,2761,118 
Total current assets:57,52954,06960,16071,14187,28384,75838,676
Noncurrent Assets
Operating lease, right-of-use asset5,924 485
Property, plant and equipment51,70843,84142,21245,64039,07437,30037,922
Intangible assets, net (including goodwill)44,9105,0197,60238,71241,29643,87946,462
Goodwill41,0774,3194,3196,4466,4466,4466,446
Intangible assets, net (excluding goodwill)3,8337003,28332,26634,85037,43340,016
Deferred tax assets, net 18,57317,06015,637
Other undisclosed noncurrent assets246486     
Total noncurrent assets:102,78849,34650,29984,35298,94398,239100,021
TOTAL ASSETS:160,317103,415110,459155,493186,226182,997138,697
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,0856,3295,16518,67517,85114,0254,971
Accounts payable2,0851,8049894,5107,9544,1321,553
Accrued liabilities 4,5254,17614,1659,8979,8933,418
Debt 1,474148  2,2364,516
Due to related parties2,039      
Disposal group, including discontinued operation  1,172    
Business combination, contingent consideration, liability   10,35432,053  
Other undisclosed current liabilities13,611      
Total current liabilities:17,7357,8036,48529,02949,90416,2619,487
Noncurrent Liabilities
Long-term debt and lease obligation97,059108,097110,68664,24353,59822,15225,244
Long-term debt, excluding current maturities92,127108,097110,31964,24353,59822,15225,244
Operating lease, liability4,932 367
Liabilities, other than long-term debt3,3691,248 80,55850,360  
Deferred revenue 1,248 
Due to related parties3,369      
Business combination, contingent consideration, liability   80,55850,360  
Other undisclosed noncurrent liabilities90367 1,1633,51672,97163,616
Total noncurrent liabilities:100,518109,712110,686145,964107,47495,12388,860
Total liabilities:118,253117,515117,171174,993157,378111,38498,347
Stockholders' equity
Stockholders' equity attributable to parent42,064(14,100)(6,712)(19,500)28,84871,61340,350
Common stock46728623321819119092
Additional paid in capital287,351219,998199,938168,535140,006132,69171,321
Accumulated other comprehensive loss    (1)  
Accumulated deficit(245,754)(234,384)(206,883)(188,253)(111,348)(61,268)(31,063)
Total stockholders' equity:42,064(14,100)(6,712)(19,500)28,84871,61340,350
TOTAL LIABILITIES AND EQUITY:160,317103,415110,459155,493186,226182,997138,697

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues75,36066,49999,21977,34771,83469,33751,952
Cost of revenue(55,537)(54,134)(53,097)(46,676)(46,177)(41,514)(31,740)
Cost of goods and services sold(55,537)(54,134)(50,981)(43,160)(38,193)(37,152)(28,054)
Gross profit:19,82312,36546,12230,67125,65727,82320,212
Operating expenses(19,411)(20,707)(22,492)(84,714)(65,968)(53,596)(27,182)
Operating income (loss):412(8,342)23,630(54,043)(40,311)(25,773)(6,970)
Nonoperating income
(Investment Income, Nonoperating)
   5123854912
Interest and debt expense(11,782)(19,159)(19,806)(8,756)(12,034)(5,588)(5,560)
Income (loss) from continuing operations before equity method investments, income taxes:(11,370)(27,501)3,824(62,287)(51,960)(31,312)(12,518)
Other undisclosed income from continuing operations before income taxes  19,806    
Income (loss) from continuing operations before income taxes:(11,370)(27,501)23,630(62,287)(51,960)(31,312)(12,518)
Income tax expense (benefit)6777,135(1,012)(17,436)1,8801,10715,551
Income (loss) from continuing operations:(10,693)(20,366)22,618(79,723)(50,080)(30,205)3,033
Loss from discontinued operations  (23,255)    
Income (loss) before gain (loss) on sale of properties:(10,693)(20,366)(637)(79,723)(50,080)(30,205)3,033
Other undisclosed net loss(677)(7,135)(17,993)    
Net income (loss) available to common stockholders, basic:(11,370)(27,501)(18,630)(79,723)(50,080)(30,205)3,033
Dilutive securities, effect on basic earnings per share      (1,174)
Net income (loss) available to common stockholders, diluted:(11,370)(27,501)(18,630)(79,723)(50,080)(30,205)1,859

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss):(11,370)(27,501)(18,630)(79,723)(50,080)(30,205)3,033
Other comprehensive income (loss)   1(1)  
Comprehensive income (loss), net of tax, attributable to parent:(11,370)(27,501)(18,630)(79,722)(50,081)(30,205)3,033

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: